Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting

Reuters11-14

Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting

Curis Inc., a biotechnology company focused on the development of emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor, has announced that it will present new clinical and preclinical data at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025. The presentations will include clinical data on emavusertib and BTKi in primary and secondary central nervous system lymphomas (PCNSL and SCNSL), as well as preclinical data on emavusertib. The results are scheduled to be presented by researchers from institutions including Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, and the University of Florida. Presentations will cover topics such as genetic mutation profiles, CNS pharmacokinetics, safety and efficacy of drug combinations, and potential efficacy signals in CNS lymphoma patients. The results will be presented at the conference and have not yet been disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE24901) on November 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583850473?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583850473","market":"nz","top_or_hot":-1,"title":"Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Curis Inc., a biotechnology company focused on the development of emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor, has announced that it will present new clinical and preclinical data at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025. The presentations will include clinical data on emavusertib and BTKi in primary and secondary central nervous system lymphomas (PCNSL and SCNSL), as well as preclinical data on emavusertib. The results are scheduled to be presented by researchers from institutions including Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, and the University of Florida. Presentations will cover topics such as genetic mutation profiles, CNS pharmacokinetics, safety and efficacy of drug combinations, and potential efficacy signals in CNS lymphoma patients. The results will be presented at the conference and have not yet been disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE24901) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCuris Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 22:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Curis Inc., a biotechnology company focused on the development of emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor, has announced that it will present new clinical and preclinical data at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025. The presentations will include clinical data on emavusertib and BTKi in primary and secondary central nervous system lymphomas (PCNSL and SCNSL), as well as preclinical data on emavusertib. The results are scheduled to be presented by researchers from institutions including Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, and the University of Florida. Presentations will cover topics such as genetic mutation profiles, CNS pharmacokinetics, safety and efficacy of drug combinations, and potential efficacy signals in CNS lymphoma patients. The results will be presented at the conference and have not yet been disclosed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE24901) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL20tMBT:1","article_id":"2583850473","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583850473","pubTimestamp":1763130403,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Curis Inc., a biotechnology company focused on the development of emavusertib , an orally available small molecule IRAK4 inhibitor, has announced that it will present new clinical and preclinical data at the 30th Annual Meeting of the Society for Neuro-Oncology  from November 19-23, 2025. The presentations will include clinical data on emavusertib and BTKi in primary and secondary central nervous system lymphomas , as well as preclinical data on emavusertib. The results are scheduled to be presented by researchers from institutions including Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, and the University of Florida. Presentations will cover topics such as genetic mutation profiles, CNS pharmacokinetics, safety and efficacy of drug combinations, and potential efficacy signals in CNS lymphoma patients. The results will be presented at the conference and have not yet been disclosed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CRIS":"居里"},"translate_title":"Curis在SNO会议上报告Emavusertib治疗中枢神经系统淋巴瘤的有希望的临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRIS":0.9},"content_text":"Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting\n    \n\n        Curis Inc., a biotechnology company focused on the development of emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor, has announced that it will present new clinical and preclinical data at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) from November 19-23, 2025. The presentations will include clinical data on emavusertib and BTKi in primary and secondary central nervous system lymphomas (PCNSL and SCNSL), as well as preclinical data on emavusertib. The results are scheduled to be presented by researchers from institutions including Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic, and the University of Florida. Presentations will cover topics such as genetic mutation profiles, CNS pharmacokinetics, safety and efficacy of drug combinations, and potential efficacy signals in CNS lymphoma patients. The results will be presented at the conference and have not yet been disclosed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE24901) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583850473","isCrawlerRequest":true}